Expansion of a recent class of broad-spectrum antifungal agents: the echinocandins


Submitted: 17 February 2014
Accepted: 17 February 2014
Published: 30 September 2009
Abstract Views: 672
PDF: 643
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The echinocandins show comparable efficacy in the treatment of candidemia and invasive candidiasis. Caspofungin and micafungin appear to be similarly efficacious in salvage therapy in aspergillosis; anidulafungin has excellent in vitro activity against Aspergillus species but as yet there are no sufficient clinical data for anidulafungin in this disease state. Each drug has minor advantages and disadvantages compared to the others of the same classe; however, there are large differences in the approved indications for the different drugs. The formulary selection process should consider the direct and indirect costs of the single agents; the characteristics of the patient population at risk for invasive mycosis, such as frequent use of interacting drugs and the burden of monitoring plasma drug levels of drugs; and the implications of using products for indications which have not been still approved (off-label indications).

Manfredi, R. (2009). Expansion of a recent class of broad-spectrum antifungal agents: the echinocandins. Microbiologia Medica, 24(3). https://doi.org/10.4081/mm.2009.2522

Downloads

Download data is not yet available.

Citations